DOCSLIB.ORG

( 12 ) United States Patent

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US010385067B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 385, 067 B2 Carra et al. (45 ) Date of Patent: Aug. 20 , 2019 (54 ) SODIUM (2R , 55 , 13AR ) - 7 , 9 -DIOX0 - 10 ( 56 ) References Cited ( 2 , 4 ,6 - TRIFLUOROBENZYL )CARBAMOYL ) 2 , 3 , 4 , 5 , 7 , 9 , 13 , 13A -OCTAHYDRO - 2 , 5 U . S . PATENT DOCUMENTS METHANOPYRIDO [ 1 ' , 2 ' : 4 , 5 ]PYRAZINO 5 , 814 ,639 A 9 / 1998 Liotta et al . [ 2 , 1 - B ] [ 1 , 3 ]OXAZEPIN - 8 - OLATE 5 , 914 , 331 A 6 / 1999 Liotta et al . 5 ,922 ,695 A 7 / 1999 Arimilli et al . 5 , 935 , 946 A 8 / 1999 Munger, Jr . et al. (71 ) Applicant: Gilead Sciences , Inc ., Foster Ctiy , CA 5 , 977 , 089 A 11/ 1999 Arimilli et al. (US ) 6 ,043 , 230 A 3 / 2000 Arimilli et al. 6 ,620 , 841 B1 9 / 2003 Fujishita et al . (72 ) Inventors : Ernest A . Carra , Foster City , CA ( US ) ; 6 ,642 , 245 B1 11/ 2003 Liotta et al. 6 , 703 , 396 B1 3 / 2004 Liotta et al . Irene Chen , San Mateo , CA (US ) ; 7 , 176 , 220 B2 2 /2007 Satoh et al. Vahid Zia , Palo Alto , CA (US ) 7 ,419 , 969 B2 9 / 2008 Naidu et al. 7 , 550 , 463 B2 6 / 2009 Yoshida (73 ) Assignee : Gilead Sciences , Inc. , Foster City , CA 7 ,635 , 704 B2 12 /2009 Satoh et al. 7 , 858 , 788 B2 12 / 2010 Yoshida et al . (US ) 8 , 129 , 385 B2 3 / 2012 Johns et al . 8 , 148 , 374 B2 4 / 2012 Desai et al. ( * ) Notice : Subject to any disclaimer , the term of this 8 , 188 , 271 B2 5 / 2012 Yoshida et al . patent is extended or adjusted under 35 8 ,410 , 103 B2 4 / 2013 Johns et al . U . S . C . 154 ( b ) by 0 days . 8 , 592 , 397 B2 11 / 2013 Dahl et al . 8 ,633 , 219 B2 1 / 2014 Matsuzaki et al. 8 ,716 , 264 B2 5 / 2014 Dahl et al . (21 ) Appl. No. : 15/ 624 , 166 8 , 778 , 943 B2 7 / 2014 Johns et al. 8 , 835 , 461 B2 9 / 2014 Fujishita et al . (22 ) Filed : Jun . 15 , 2017 8 , 981 , 103 B2 3 / 2015 Ando et al. 8 ,987 ,441 B2 3 /2015 Takahashi et al. 9 ,051 , 337 B2 6 / 2015 Johns et al. (65 ) Prior Publication Data 9 ,216 , 996 B2 12 /2015 Jin et al . US 2018 /0065986 A1 Mar. 8 , 2018 9 , 663 , 528 B2 5 / 2017 Desai et al . 9 ,682 ,084 B2 6 / 2017 Carra et al . 9 ,708 , 342 B2 * 7 /2017 Carra · CO7D 498 / 18 9 , 732 , 092 B2 8 / 2017 Jin et al . Related U . S . Application Data 9 , 815 , 835 B211 / 2017 Akiyama et al . 10 ,035 , 809 B2 7 / 2018 Bacon et al. (62 ) Division of application No . 14 /744 ,915 , filed on Jun . 10 ,098 ,886 B2 10 / 2018 Carra et al. 19 , 2015 , now Pat. No. 9 , 708 , 342 . 2005 /0054645 A1 3 /2005 Miyazaki et al . 2005 / 0137224 A1 6 / 2005 Shima et al . 2006 / 0086401 A1 4 / 2006 Sato 2007 /0072831 A1 3 / 2007 Cai et al. (60 ) Provisional application No . 62 /015 ,245 , filed on Jun . 2007 /0117848 A1 5 / 2007 Puerta et al . 20 , 2014 2008 / 0020010 Al 1 / 2008 Nair et al. 2008 / 0139579 Al 6 / 2008 Morrissette et al. (51 ) Int. Ci. 2008 / 0161271 Al 7 /2008 Yoshida et al . C07D 498 / 18 ( 2006 .01 ) (Continued ) A61K 31 /553 ( 2006 . 01 ) A61K 31 /675 ( 2006 .01 ) FOREIGN PATENT DOCUMENTS A61K 31 /513 ( 2006 .01 ) DE 2244012 Al 3 / 1973 C07D 498 / 14 ( 2006 .01 ) DE 2552871 A1 7 / 1976 A61K 9 / 20 ( 2006 . 01 ) A61K 31/ 537 ( 2006 . 01 ) ( Continued ) A61K 31 / 685 ( 2006 . 01) A61K 45 / 06 ( 2006 .01 ) OTHER PUBLICATIONS A61K 31/ 683 ( 2006 .01 ) Agrawal, et al . ( 2012 ) “ Probing Chelation Motifs in HIV Integrase ( 52 ) U . S . CI. Inhibitors ” Proc . Natl. Acad . Sci. U . S . A . ; 109 ( 7 ) :2251 - 2256 . CPC . .. .. .. .. .. C07D 498 / 18 ( 2013 .01 ) ; A61K 9 / 20 ( 2013 .01 ) ; A61K 9 /2054 (2013 . 01 ) ; A61K ( Continued ) 31/ 513 ( 2013 .01 ) ; A61K 31/ 537 ( 2013 .01 ) ; Primary Examiner — Kahsay Habte A61K 31 /553 ( 2013 . 01 ) ; A61K 31 /675 (2013 .01 ) ; A61K 31/ 683 ( 2013 .01 ) ; A61K (57 ) ABSTRACT 31/ 685 ( 2013 . 01 ) ; A61K 45 / 06 ( 2013 . 01) ; The present invention relates to sodium (2R ,55 ,13aR ) - 7 , 9 C07D 498 / 14 ( 2013 .01 ) ; C07B 2200 / 13 dioxo - 10 - ( ( 2 , 4 , 6 - trifluorobenzyl) carbamoyl) - 2 , 3 ,4 , 5 , 7 , 9 , 13 , (2013 . 01 ) 13a -octahydro - 2 , 5 -methanopyrido [ 1' , 2' : 4 , 5 ]pyrazino [ 2 , 1 - b ] (58 ) Field of Classification Search [ 1 , 3 ] oxazepin - 8 - olate Form I, pharmaceutical formulations, CPC .. CO7D 498 / 18 ; A61K 31/ 553 ; A61K 31/ 675 ; and uses thereof for treating or prophylactically preventing A61K 31 /513 an HIV infection . USPC . .. 544 /95 ; 514 /81 , 229 . 5 See application file for complete search history . 19 Claims, 7 Drawing Sheets US 10 ,385 , 067 B2 Page 2 ( 56 ) References Cited WO WO - 2010 /011812 A1 1 / 2010 Wo WO - 2010 /011813 Al 1 / 2010 U . S . PATENT DOCUMENTS WO WO - 2010 /011814 A1 1 / 2010 WO WO - 2010 /011815 A1 1 / 2010 2008 / 0280945 A1 11/ 2008 Lohani et al . WO WO - 2010 / 011816 A1 1 / 2010 2009 /0036684 AL 2 / 2009 Matsuda et al . WO WO - 2010 /011818 A1 1 / 2010 2009 /0143356 A16 / 2009 Yoshida et al. Wo WO - 2010 /011819 A1 1 / 2010 2009 /0253677 A 10 / 2009 Beaulieu et al . wo WO - 2010 / 068253 A1 6 / 2010 2009 /0318702 Al 12 / 2009 Matsuda et al . wo WO - 2010 /068262 Al 6 / 2010 2010 / 0068695 A1 3 / 2010 Kiyama et al. WO WO - 2011 / 094150 A1 8 / 2011 2012 / 0022251 A1 1 / 2012 Sumino et al . WO WO - 2011/ 105590 A1 9 / 2011 2012 /0108564 Al 5 / 2012 Miyazaki et al. WO WO - 2011 / 119566 A1 9 / 2011 2012 /0232117 Al 9 / 2012 Bae et al . WO WO - 2012 / 009009 A2 1 /2012 2013 /0006485 Al 1 / 2013 Kwasniewski WO WO - 2012 /018065 AL 2 /2012 2014 / 0011995 Al 1 / 2014 Sumino et al . WO WO - 2012 / 106534 A2 8 / 2012 2014 / 0094605 Al 4 / 2014 Yoshida et al. WO WO - 2012 / 151361 AL 11 /2012 2014 /0221355 A1 8 / 2014 Lazerwith et al. WO WO - 2012 / 151567 AL 11 / 2012 2014 /0221356 A1 8 / 2014 Jin et al . WO WO - 2013 /038407 Al 3 / 2013 2014 / 0221378 Al 8 / 2014 Miyazaki et al . WO WO - 2013 /054862 A1 4 / 2013 2014 / 0243521 Al 8 / 2014 Yoshida et al . WO WO - 2013 /087581 A1 6 / 2013 2014 / 0256937 Al 9 / 2014 Akiyama WO WO - 2014 / 008636 A1 1 / 2014 2015 / 0232479 AL 8 / 2015 Johns et al . WO WO - 2014 /011769 Al 1 / 2014 2015 /0368264 AL 12 / 2015 Chiu et al. WO WO - 2014 /014933 A1 1 / 2014 2017 / 0189337 A1 7 / 2017 Collman et al. WO WO - 2014 /018449 Al 1 / 2014 2017 / 0260204 AL 9 / 2017 Bacon et al . WO WO - 2014 / 022707 Al 2 / 2014 2017 /0333438 A1 11/ 2017 Carra et al. WO WO - 2014 / 074675 Al 5 / 2014 2018 / 0022757 AL 1 /2018 Chiu et al. WO WO - 2014 / 093941 A 6 / 2014 2019/ 0092787 Al 3 / 2019 Bacon et al. WO WO - 2014 /099586 A1 6 / 2014 WO WO - 2014 / 100077 A 6 / 2014 Wo WO - 2014 / 100323 Al 6 / 2014 FOREIGN PATENT DOCUMENTS WO WO - 2014 / 104279 Al 7 / 2014 WO WO - 2014 / 200880 A1 12 / 2014 DE 2658401 A1 7 / 1978 WO WO - 2015 /039348 A1 3 / 2015 EP 0154199 A2 9 / 1985 WO WO - 2015 /048363 A1 4 / 2015 EP 0378067 A2 7 / 1990 WO WO - 2015 / 089847 A1 6 / 2015 EP 0456073 A2 11 / 1991 wo WO - 2015 /095258 A1 6 / 2015 EP 1422218 A1 5 / 2004 WO WO - 2015 / 110897 A2 7 / 2015 EP 1544199 A1 6 / 2005 WO WO - 2015 / 138933 A1 9 / 2015 EP 1874117 A1 1 / 2008 WO WO - 2015 / 196116 A1 12 / 2015 EP 2412709 A1 2 / 2012 EP 2465580 A1 6 / 2012 EP 2527007 Al 11 /2012 OTHER PUBLICATIONS EP 2602260 A1 6 / 2013 GB 2345058 A 6 / 2000 AIDS treatment Guidelines ( 2013 ) " Aids info Guidelines for the WO WO - 1994 /017090 Al 8 / 1994 Use of Antiretroviral Agents in HIV - 1 - Infected Adults and Adoles WO WO - 1999 /005142 A1 2 / 1999 cents , ” [ downloaded from http : / /aidsinfo .nih . gov / guidelines on Mar. WO WO - 1999 / 25345 Al 5 / 1999 WO WO - 2000 /027823 A1 5 / 2000 15 , 2013 ] , 267 pages . WO WO - 2003 /030897 A1 4 / 2003 Akiyama, et al . (2013 ) “ Discovery of Novel HIV Integrase Inhibi WO WO - 2003 /035077 Al 5 / 2003 tors Part 2 . Selection and Evaluation of an Azabicylic Carbamoyl WO WO - 2004 /004657 A2 1 / 2004 Pyridone as apre - Clinical Candidate ” Poster , American Chemical WO WO - 2004 /024078 A2 3 / 2004 Society National Meeting and Exposition ; Apr. 7 - 11 ; New Orleans , WO WO - 2005 /016927 Al 2 / 2005 LA . WO WO - 2005 /042533 A2 5 / 2005 Andrews, C . et al. ( 2014 ) “ Long - Acting Integrase Inhibitor Protects WO WO - 2005 /074513 A2 8 / 2005 Macaques from Intrarectal Simian Human Immunodeficiency Virus ," WO WO - 2005 / 110399 A2 11 / 2005 Science 343 : 1151- 1154 . wo WO - 2005 / 110414 A2 11 / 2005 Atsushi M . et al . ( 2001) “ Regioselective Oxygenations of S — Trans WO WO - 2005 / 112930 A1 12 / 2005 Dienes, Silyl Dienol Ethers ( SDEs) , by Triphenyl Phosphite Ozonide WO WO - 2005 / 113508 AL 12 / 2005 ( TPPO ) and It’ s Mechanistic Study ” The Journal of Organic Chem WO WO - 2005 / 113509 Al 12 /2005 WO WO - 2006 / 028523 A2 3 / 2006 istry 66 ( 10 ) : 3548 - 3553 .
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0306098 A1 Mutz Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2008/0306098 A1 Mutz Et Al

    US 200803 06098A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0306098 A1 Mutz et al. (43) Pub. Date: Dec. 11, 2008 (54) PHARMACOKINETICS OF PROTEASE Publication Classification INHIBITORS AND OTHER DRUGS (51) Int. Cl. A 6LX 3L/505 (2006.01) (76) Inventors: Mitchell W. Mutz, La Jolla, CA A63L/4353 (2006.01) (US); Jason E. Gestwicki, Ann C07D 49/12 (2006.01) Arbor, MI (US) C07D 239/04 (2006.01) A6IP3 L/18 (2006.01) Correspondence Address: (52) U.S. Cl. ............ 514/274: 514/291; 546/90; 54.4/316 MINTZ, LEVIN, COHN, FERRIS, GLOVSKY (57) ABSTRACT AND POPEO, PC 5 Palo Alto Square - 6th Floor,3000 El Camino Real A method for modulating at least one pharmacokinetic prop PALO ALTO, CA 94306-2155 (US) erty of a protease inhibitor upon administration to a host is provided. One administers to the host an effective amount of a bifunctional compound of less than about 5000 daltons (21) Appl. No.: 12/151,329 comprising the protease inhibitor or an active derivative thereof and a pharmacokinetic modulating moiety. The phar (22) Filed: May 5, 2008 macokinetic modulating moiety binds to at least one intrac ellular protein. The bifunctional compound has at least one (30) Foreign Application Priority Data modulated pharmacokinetic property upon administration to the hostas compared to a free drug control that comprises the Nov. 6, 2006 (US) ................. PCT/US2006/043400 protease inhibitor. FKBP-binding FKBP-binding interface interface Conjugate Target Binding Calcineurin-binding interface Patent Application Publication Dec. 11, 2008 Sheet 1 of 11 US 2008/0306.098 A1 O) \iO Ol cy A- S' O I N CD (5.
  • HIV-Infected Patients

    HIV-Infected Patients

    New Drugs for the Treatment-Experienced Patient Joseph Eron, md Associate Professor of Medicine and Director, Clinical Core unc Center for aids Research, University of North Carolina at Chapel Hill Summary by Tim Horn Edited by Jay Dobkin, md; Michael Saag, md reatment options for antiretro- humans by adenosine deaminase into D- Deeks and his colleagues in 1998 demon- viral-experienced patients leave a dioxolane guanine (dxg), a metabolite that strated a 1 log reduction in hiv-rna in hiv- lot to be desired. According to Dr. has potent activity against hiv and hbv. infected patients—more than 50% of whom Joe Eron, patients who have treat- According to in vitro data presented at were treatment-experienced—who received ment experience in all three classes the 3rd International Workshop on hiv tenofovir df 300 mg once daily as of currently available antiretrovi- Drug Resistance and Treatment Strategies, monotherapy for 28 days (Deeks, 1998). Trals have, at best, a 30% chance of re- held in June 1999, dapd was found to in- According to in vitro data presented by ducing their viral load to levels below 400 hibit wild-type and mutant isolates resistant Gilead’s Dr. Michael Miller at the recent copies/mL upon initiating a salvage regi- to azt (Retrovir) and 3TC (Borroto-Esoda, 4th International Resistance Workshop, the men. Cross-resistance within each class of 1999). The drug was also reported to be ac- resistance pattern for tenofovir df is simi- drugs, particularly the protease inhibitors tive against strains collected from patients lar to that of its chemical predecessor adefo- (pis) and non-nucleoside reverse tran- who have failed various nrti and nnrti vir, a compound no longer in development scriptase inhibitors (nnrtis), essentially combination therapies, including those for the treatment of hiv (Miller, 2000).
  • Download Article PDF/Slides

    Download Article PDF/Slides

    New Antiretrovirals in Development: Reprinted from The PRN Notebook,™ june 2002. Dr. James F. Braun, Editor-in-Chief. Tim Horn, Executive Editor. Published in New York City by the Physicians’ Research Network, Inc.,® John Graham Brown, Executive Director. For further information and other articles The View in 2002 available online, visit http://www.PRN.org All rights reserved. © june 2002. Roy “Trip” Gulick, md, mph Associate Professor of Medicine, Weill Medical College of Cornell University Director, Cornell Clinical Trials Unit, New York, New York Summary by Tim Horn Edited by Scott Hammer, md espite the fact that 16 antiretro- tiviral activity of emtricitabine was estab- Preliminary results from two random- virals are approved for use in the lished, with total daily doses of 200 mg or ized studies—FTC-302 and FTC-303—were United States, there is an indis- more producing the greatest median viral reported by Dr. Charles van der Horst and putable need for new anti-hiv com- load suppression: 1.72-1.92 log. Based on his colleagues at the 8th croi, held in Feb- pounds that have potent and these data, a once-daily dose of 200 mg ruary 2001 in Chicago (van der Horst, durable efficacy profiles, unique re- was selected for further long-term clinical 2001). FTC-302 was a blinded comparison sistance patterns, patient-friendly dosing study. “This is what we’re looking forward of emtricitabine and lamivudine, both in schedules, and minimal toxicities. To pro- to with emtricitabine,” commented Dr. combination with stavudine (Zerit) and vide prn with a glimpse of drugs current- Gulick.
  • Canadian HIV/AIDS Pharmacists Network (CHAP) Newsletter – April 2000

    Canadian HIV/AIDS Pharmacists Network (CHAP) Newsletter – April 2000

    1 Canadian HIV/AIDS Pharmacists Network (CHAP) Newsletter – April 2000 Happy Spring! It is pouring cats and dogs here in “sunny” Alberta today, but the good news is that the grass and trees are green (yes I am an optimist). I even had to shake off the dust from my umbrella! I won’t complain because Spring is finally here……. Hurray! As you know, I have officially taken over the Chair from Kathy Slayter (aka “Mom”). This is my first attempt at a newsletter so please be patient with me! Social News Well I am sure everyone has heard the good news but I would like to officially congratulate Kathy and Mike on the birth of their little boy, Ethan James Tucker, on December 11, 1999. Congratulations Kathy! New Members I would like to officially welcome the following new members: Laura Park-Wyllie who has taken over Michelle Foisy’s position as HIV Primary Care Pharmacist at the St. Michael’s Hospital, Health Centre at 410 (formerly Wellesley Health Centre). Deborah Kelly who is as an Assistant Professor of Clinical Pharmacy at Memorial University in Newfoundland and Clinical Pharmacy Specialist at Health Care Corp of St. John’s. Kimberly Montgomery who is a Pharmacist at the Southern Alberta Clinic (taking over from Nikola Ostrop). Unfortunately, Kim will not be with us long. She is getting married in August and then will be moving to Newfoundland. Her last day at the clinic will be June 30, 2000. Congratulations on your upcoming wedding Kim! For those of you interested, there is an opening at the SAC and you can contact Kimberly for more details… 2 CAHR Update I thought the CAHR conference was excellent and the Network meeting went well (considering all of the problems we had arranging the first Network meeting of the millenium!).
  • Meeting Report: 26Th International Conference on Antiviral Research Q

    Meeting Report: 26Th International Conference on Antiviral Research Q

    Antiviral Research 100 (2013) 276–285 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Review Meeting report: 26th International Conference on Antiviral Research q R. Anthony Vere Hodge Vere Hodge Antivirals Ltd, Old Denshott, Leigh, Reigate, Surrey, UK article info abstract Article history: The 26th International Conference on Antiviral Research (ICAR) was held in San Francisco, California from Received 2 August 2013 May 11 to 15, 2013. This article summarizes the principal invited lectures at the meeting. The opening Accepted 8 August 2013 symposium on the legacy of the late Antonín Holy´ included presentations on his pioneering work with Available online 21 August 2013 nucleotide analogs, which led to the development of several antiviral drugs including tenofovir. This drug has transformed the treatment of HIV infection and has recently become the first-line therapy for chronic Keywords: hepatitis B. The Gertrude Elion Award lecturer described the anti-HIV activities of the CCR5 inhibitor Human immunodeficiency virus cenicriviroc and the reverse transcriptase inhibitor festinavirÒ, and also reviewed the evaluation of bio- Hepatitis B degradable nanoparticles with adjuvant activity. The William Prusoff Award winner reported on the cre- Hepatitis C Herpesviruses ation of NAOMI, a computer model with 21 enzymes to predict the activity of nucleoside analogs against Antiviral therapy hepatitis C virus (HCV). Other invited lecturers discussed the development of countermeasures against severe dengue and the potential of RNA virus capping and repair enzymes as drug targets. Topics in the clinical symposium included the current status of the anti-HCV compounds sovaprevir, ACH-3102, miravirsen and ALS-2200; the evaluation of single-tablet regimens for HIV infection; and the investiga- tion of cytomegalovirus resistance to CMX001.
  • Modifications to the Harmonized Tariff Schedule of the United States To

    Modifications to the Harmonized Tariff Schedule of the United States To

    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
  • This Project Has Been Supported with Unrestriced Grants from Abbvie Gilead Sciences HEXAL Janssen-Cilag MSD Viiv Healthcare By

    This Project Has Been Supported with Unrestriced Grants from Abbvie Gilead Sciences HEXAL Janssen-Cilag MSD Viiv Healthcare By

    This project has been supported with unrestriced grants from AbbVie Gilead Sciences HEXAL Janssen-Cilag MSD ViiV Healthcare By Marcus Altfeld, Hamburg/Boston (USA) Achim Barmeyer, Dortmund Georg Behrens, Hannover Dirk Berzow, Hamburg Christoph Boesecke, Bonn Patrick Braun, Aachen Thomas Buhk, Hamburg Rob Camp, Barcelona (Spain/USA) Rika Draenert, Munich Christian Eggers, Linz (Austria) Stefan Esser, Essen Gerd Fätkenheuer, Cologne Gunar Günther, Windhoek (Namibia) Thomas Harrer, Erlangen Christian Herzmann, Borstel Christian Hoffmann, Hamburg Heinz-August Horst, Kiel Martin Hower, Dortmund Christoph Lange, Borstel Thore Lorenzen, Hamburg Tim Niehues, Krefeld Christian Noah, Hamburg Ramona Pauli, Munich Ansgar Rieke, Koblenz Jürgen Kurt Rockstroh, Bonn Thorsten Rosenkranz, Hamburg Bernhard Schaaf, Dortmund Ulrike Sonnenberg-Schwan, Munich Christoph D. Spinner, Munich Thomas Splettstoesser (Figures), Berlin Matthias Stoll, Hannover Hendrik Streeck, Essen/Boston (USA) Jan Thoden, Freiburg Markus Unnewehr, Dortmund Mechthild Vocks-Hauck, Berlin Jan-Christian Wasmuth, Bonn Michael Weigel, Schweinfurt Thomas Weitzel, Santiago (Chile) Eva Wolf, Munich HIV 2015/16 www.hivbook.com Edited by Christian Hoffmann and Jürgen K. Rockstroh Medizin Fokus Verlag IV Christian Hoffmann, M.D., Ph.D. ICH Stadtmitte (Infektionsmedizinisches Centrum Hamburg) Glockengiesserwall 1 20095 Hamburg, Germany Phone: + 49 40 2800 4200 Fax: + 49 40 2800 42020 [email protected] Jürgen K. Rockstroh, M.D., Ph.D. Department of Medicine I University of Bonn Sigmund-Freud-Strasse 25 53105 Bonn, Germany Phone: + 49 228 287 6558 Fax: + 49 228 287 5034 [email protected] HIV Medicine is an ever-changing field. The editors and authors of HIV 2015/16 have made every effort to provide information that is accurate and complete as of the date of publication.
  • Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination (F/Taf Fdc)

    Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination (F/Taf Fdc)

    SECTION 2.7.1—SUMMARY OF BIOPHARMACEUTICAL STUDIES AND ASSOCIATED ANALYTICAL METHODS EMTRICITABINE/TENOFOVIR ALAFENAMIDE FIXED-DOSE COMBINATION (F/TAF FDC) Gilead Sciences 20 CONFIDENTIAL AND PROPRIETARY INFORMATION F/TAF 2.7.1 Summary of Biopharmaceutical Studies Final TABLE OF CONTENTS SECTION 2.7.1—SUMMARY OF BIOPHARMACEUTICAL STUDIES AND ASSOCIATED ANALYTICAL METHODS.................................................................................................................................1 TABLE OF CONTENTS ..............................................................................................................................................2 LIST OF IN-TEXT TABLES........................................................................................................................................3 GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS......................................................................5 PHARMACOKINETIC ABBREVIATIONS AND DEFINITIONS ............................................................................7 1. SUMMARY OF BIOPHARMACEUTICAL STUDIES AND ASSOCIATED ANALYTICAL METHODS ...........................................................................................................................................................8 1.1. Background and Overview.......................................................................................................................8 1.1.1. Formulation Development......................................................................................................9
  • HIV Medicine 2003

    HIV Medicine 2003

    Contributing Authors Marcus Altfeld – Boston Georg Behrens – Melbourne Mario Ostrowski – Toronto Andrea Rubbert – Köln Christiane Schieferstein – Frankfurt Reinhold E. Schmidt – Hannover Bruce D. Walker – Boston Eva Wolf – München HIV Medicine 2003 www.HIVMedicine.com Edited by Christian Hoffmann and Bernd Sebastian Kamps Flying Publisher 3 Editors Christian Hoffmann, M.D. University of Schleswig Holstein Infectious Diseases Outpatient Clinic Kiel Chemnitzstr. 33 24116 Kiel, Germany Fax: + 49 431 1697 1273 www.HIVMedicine.com www.SARSReference.com Bernd Sebastian Kamps, M.D. Flying Publisher Rue Saulnier 75009 Paris France www.FlyingPublisher.com HIV Medicine is an ever-changing field. The editors and authors of HIV Medicine 2003 have made every effort to provide information that is accurate and complete as of the date of publication. However, in view of the rapid changes occurring in medical science, HIV prevention and policy, as well as the possibility of human error, this site may contain technical inaccuracies, typographical or other errors. Readers are advised to check the product information currently provided by the manufacturer of each drug to be administered to verify the recommended dose, the method and duration of administration, and contraindications. It is the responsibility of the treating physician who relies on experience and knowledge about the patient to determine dosages and the best treatment for the patient. The information contained herein is provided "as is" and without warranty of any kind. The contributors to this site, including Flying Publisher and AmedeoGroup, disclaim responsibility for any errors or omissions or for results obtained from the use of information contained herein. © 2003 by Flying Publisher – Paris, Cagliari, Wuppertal, Sevilla Assistant Editors: Nyasha Bakare, Dianne Lydtin Design: Attilio Baghino, www.a4w.it ISBN: 3-924774-37-4 4 Preface Hardly any field of medicine has ever undergone a similar stormy development to that of the therapy of HIV infection.
  • I Regulations

    I Regulations

    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
  • Downloaded In.Sdf Format from the Pubchem Database (

    Downloaded In.Sdf Format from the Pubchem Database (

    In silico Prediction of Mozenavir as potential drug for SARS-CoV-2 infection via Binding Multiple Drug Targets Estari Mamidalaa*, Rakesh Davellab, Swapna Gurrapuc, Munipally Praveen Kumard, Abhiave a,b,c,d Infectious Diseases Research Lab, Department of Zoology, Kakatiya University, Warangal, Telangana-506 009, India e Division of ISRM, Indian Council of Medical Research (ICMR), Department of Health Research, New Delhi, India *Corresponding should be addressed to Estari Mamidala: [email protected] Keywords: Mozenavir, SARS-CoV-2, Mpro, ACE-2, RdRp, S glycoprotein, Furin ABSTRACT Since the epidemic began in November 2019, no viable medicine against SARS-CoV-2 has been discovered. The typical medication discovery strategy requires several years of rigorous research and development as well as a significant financial commitment, which is not feasible in the face of the current epidemic. Through molecular docking and dynamic simulation studies, we used the FDA-approved drug mezonavir against the most important viral targets, including spike (S) glycoprotein, Transmembrane serine protease 2 (TMPRSS2), RNA-dependent RNA polymerase (RdRp), Main protease (Mpro), human angiotensin-converting enzyme 2 (ACE-2), and furin. These targets are critical for viral replication and infection propagation because they play a key role in replication/transcription and host cell recognition. Molecular docking revealed that the antiviral medication mozenavir showed a stronger affinity for SARS-CoV-2 target proteins than reference medicines in this investigation. We discovered that mozenavir increases the complex's stability and validates the molecular docking findings using molecular dynamics modelling. Furin, a target protein of COVID-19, has a greater binding affinity (-12.04 kcal/mol) than other COVID-19 target proteins, forming different hydrogen bonds and polar and hydrophobic interactions, suggesting that it might be used as an antiviral treatment against SARS- CoV-2.